- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Spago Nanomedical AB: Spago Nanomedical announces outcome of rights issue | 163 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 10.06. | Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB | 291 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2026, at which the... ► Artikel lesen | |
| 03.06. | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 408 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 03.06. | Spago Nanomedical AB: The subscription period in Spago Nanomedical's rights issue begins today | 156 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 02.06. | Listing of subscription rights and paid subscription shares of Spago Nanomedical AB | 240 | GlobeNewswire | With effect from June 03, 2026, the subscription rights in Spago Nanomedical AB will be traded on First North Growth Market. Trading will continue up until and including June 12, 2026.
... ► Artikel lesen | |
| 02.06. | Spago Nanomedical AB: Spago Nanomedical publishes information document in connection with forthcoming rights issue | 117 | GlobeNewswire (Europe) | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 29.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.05.2026 | 405 | Xetra Newsboard | Das Instrument TAH JP3634600005 TOYOTA INDS EQUITY wird cum Kapitalmassnahme gehandelt am 29.05.2026 und ex Kapitalmassnahme am 01.06.2026 The instrument TAH JP3634600005 TOYOTA INDS EQUITY is traded... ► Artikel lesen | |
| 22.05. | Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 16 Million | 398 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 19.05. | Spago Nanomedical Publishes the Annual Report for 2025 | 368 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2025 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 18.05. | Spago Nanomedical Presents Tumorad Clinical Data at the International ANZSNM 2026 Conference | 309 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented... ► Artikel lesen | |
| 11.05. | Notice To Annual General Meeting of Spago Nanomedical AB | 278 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 11, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version prevails... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March 2026 | 407 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)JANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 22 (KSEK 338)The loss for the quarter amounted... ► Artikel lesen | |
| 06.05. | Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake | 370 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01... ► Artikel lesen | |
| 24.03. | Spago Nanomedical's Abstract on Tumorad Accepted for Presentation at Radiopharma Conference | 385 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 24, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) today announced that an abstract describing the ongoing Phase I/IIa clinical study... ► Artikel lesen | |
| 17.03. | Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation | 340 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical... ► Artikel lesen | |
| 10.03. | Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development | 375 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 10, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) announced today that Torsten Malmström has assumed the position of Director CMC & Supply. Torsten Malmström... ► Artikel lesen | |
| 05.02. | Spago Nanomedical Year-End Report January-December, 2025 | 401 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 5, 2026 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 4 (KSEK 617)The loss for the quarter... ► Artikel lesen | |
| 08.12.25 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2026 | 375 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 8, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 24.11.25 | Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue | 394 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 07.11.25 | The Subscription Period in Spago Nanomedical's Rights Issue Begins Today | 478 | ACCESS Newswire | NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,07 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | 0,00 % | Monte Rosa, BioAge plunge as Novo's setback casts a shadow over pipeline | ||
| EDGEWISE THERAPEUTICS | 38,430 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | +0,08 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -0,01 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +0,10 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,195 | +0,06 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (-2,13 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.